Oyster Point Pharma, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|
| Revenue | $24.5M | $0 | — | — |
| Operating income | −$96.7M | −$71.0M | −$4.0M | −$3.0M |
| Net income | −$100.7M | −$70.5M | −$3.8M | −$2.9M |
| Total assets | $222.6M | $197.9M | $143.2M | $5.7M |
| Total liabilities | $123.1M | $11.3M | $5.9M | $946,000 |
| Equity | $99.5M | $186.7M | $137.3M | −$38.2M |
| EPS (diluted) | $-3.87 | $-2.92 | — | — |
| Shares out. | 25.9M | 21.4M | 21.4M | 1.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- −393.9%
- Net margin
- −410.2%
- Return on equity
- −101.1%
- Return on assets
- −45.2%
- Return on capital (ROCE)
- −49.9%
- Liabilities / assets
- 55.3%
- Debt / equity
- 1.24×
- Book value / share
- $3.84
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- -0.31distress
- Accruals / assets
- −5.1%clean
- Piotroski F-Score
- 2/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 1 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- TYRVAYAOct 15, 2021
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Invopps Gp Iv, L.L.C.Director | Jan 3, 2023 | U | 917,768 | — |
| Versant Venture Capital Vi, L.P.10% owner | Jan 3, 2023 | U | 2.2M | — |
| Behbahani AliDirector | Jan 3, 2023 | D | 10,066 | — |
| New Enterprise Associates 14, L.P.10% owner | Jan 3, 2023 | U | 5.9M | — |
| Weisner Aimee SDirector | Jan 3, 2023 | D | 33,191 | — |
| Tsai BenjaminDirector | Jan 3, 2023 | U | 10,066 | — |
| Santel Donald JDirector | Jan 3, 2023 | U | 5,489 | — |
| Ozawa ClareDirector | Jan 3, 2023 | D | 11,064 | — |
| Nau JeffreyOfficer — President and CEO | Jan 29, 2022 | Tax withholding | 2,607 | $11.70 |
| Murray Mark AnthonyDirector | Jan 3, 2023 | D | 118,513 | — |
| Lochner DanielOfficer — Chief Financial Officer | Jan 29, 2022 | Tax withholding | 938 | $11.70 |
| Eliades George ChristopherDirector | Jan 3, 2023 | D | 11,761 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 3, 2023
- Results of operationsNov 10, 2022
- Entered a material agreementNov 8, 2022
- Other material eventNov 7, 2022
- Results of operationsAug 11, 2022
- Director / officer changeJul 12, 2022
- Costs from exit or disposal · Director / officer change · Other material eventJun 28, 2022
- Shareholder voteJun 8, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2023
- SC 13G/ASCHEDULE 13G/A, AMENDMENT #2Feb 14, 2023
- SC 13G/AOYSTER POINT PHARMA, INC.Feb 14, 2023
- 15-12GJan 13, 2023
- 8-K/AJan 13, 2023
- SC 13D/AJan 13, 2023
- SC 13D/ANEW ENTERPRISE ASSOCIATES 14, L.P. -- OYSTER POINT PHARMA, INC. 13D/A(#2E)Jan 9, 2023
- EFFECTJan 5, 2023
- SC 13D/AJan 5, 2023
- 4FORM 4 SUBMISSIONJan 5, 2023
- 4FORM 4 SUBMISSIONJan 4, 2023
- 4FORM 4 SUBMISSIONJan 4, 2023
- 4FORM 4 SUBMISSIONJan 4, 2023
- 4FORM 4 SUBMISSIONJan 4, 2023
- 4FORM 4 SUBMISSIONJan 4, 2023